Skip to main content

Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.

Publication ,  Journal Article
Khairnar, R; DeMora, L; Sandler, HM; Lee, WR; Villalonga-Olives, E; Mullins, CD; Palumbo, FB; Bruner, DW; Shaya, FT; Bentzen, SM; Shah, AB ...
Published in: JCO Clin Cancer Inform
June 2022

PURPOSE: To compare the predictive ability of mapping algorithms derived using cross-sectional and longitudinal data. METHODS: This methodological assessment used data from a randomized controlled noninferiority trial of patients with low-risk prostate cancer, conducted by NRG Oncology (ClinicalTrials.gov identifier: NCT00331773), which examined the efficacy of conventional schedule versus hypofractionated radiation therapy (three-dimensional conformal external beam radiation therapy/IMRT). Health-related quality-of-life data were collected using the Expanded Prostate Cancer Index Composite (EPIC), and health utilities were obtained using EuroQOL-5D-3L (EQ-5D) at baseline and 6, 12, 24, and 60 months postintervention. Mapping algorithms were estimated using ordinary least squares regression models through five-fold cross-validation in baseline cross-sectional data and combined longitudinal data from all assessment periods; random effects specifications were also estimated in longitudinal data. Predictive performance was compared using root mean square error. Longitudinal predictive ability of models obtained using baseline data was examined using mean absolute differences in the reported and predicted utilities. RESULTS: A total of 267 (and 199) patients in the estimation sample had complete EQ-5D and EPIC domain (and subdomain) data at baseline and at all subsequent assessments. Ordinary least squares models using combined data showed better predictive ability (lowest root mean square error) in the validation phase for algorithms with EPIC domain/subdomain data alone, whereas models using baseline data outperformed other specifications in the validation phase when patient covariates were also modeled. The mean absolute differences were lower for models using EPIC subdomain data compared with EPIC domain data and generally decreased as the time of assessment increased. CONCLUSION: Overall, mapping algorithms obtained using baseline cross-sectional data showed the best predictive performance. Furthermore, these models demonstrated satisfactory longitudinal predictive ability.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JCO Clin Cancer Inform

DOI

EISSN

2473-4276

Publication Date

June 2022

Volume

6

Start / End Page

e2100188

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Quality of Life
  • Prostatic Neoplasms
  • Male
  • Humans
  • Cross-Sectional Studies
  • Algorithms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khairnar, R., DeMora, L., Sandler, H. M., Lee, W. R., Villalonga-Olives, E., Mullins, C. D., … Mishra, M. V. (2022). Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform, 6, e2100188. https://doi.org/10.1200/CCI.21.00188
Khairnar, Rahul, Lyudmila DeMora, Howard M. Sandler, W Robert Lee, Ester Villalonga-Olives, C Daniel Mullins, Francis B. Palumbo, et al. “Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.JCO Clin Cancer Inform 6 (June 2022): e2100188. https://doi.org/10.1200/CCI.21.00188.
Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, et al. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform. 2022 Jun;6:e2100188.
Khairnar, Rahul, et al. “Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.JCO Clin Cancer Inform, vol. 6, June 2022, p. e2100188. Pubmed, doi:10.1200/CCI.21.00188.
Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng F, Mishra MV. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform. 2022 Jun;6:e2100188.

Published In

JCO Clin Cancer Inform

DOI

EISSN

2473-4276

Publication Date

June 2022

Volume

6

Start / End Page

e2100188

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Quality of Life
  • Prostatic Neoplasms
  • Male
  • Humans
  • Cross-Sectional Studies
  • Algorithms